mirabegron
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pharmacokinetics
Conditions
Pharmacokinetics, Healthy Subjects, Mild and Moderate Hepatic Impairment
Trial Timeline
Nov 1, 2008 → Apr 1, 2009
NCT ID
NCT01579461About mirabegron
mirabegron is a phase 1 stage product being developed by Astellas Pharma for Pharmacokinetics. The current trial status is completed. This product is registered under clinical trial identifier NCT01579461. Target conditions include Pharmacokinetics, Healthy Subjects, Mild and Moderate Hepatic Impairment.
What happened to similar drugs?
5 of 5 similar drugs in Pharmacokinetics were approved
Approved (5) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05621616 | Phase 3 | Active |
| NCT04562090 | Approved | Completed |
| NCT04501640 | Approved | Completed |
| NCT02981459 | Approved | Withdrawn |
| NCT02916693 | Phase 1/2 | Completed |
| NCT02751931 | Phase 3 | Completed |
| NCT02526979 | Phase 1 | Completed |
| NCT02495389 | Approved | Completed |
| NCT02211846 | Phase 1 | Completed |
| NCT01898624 | Pre-clinical | Completed |
| NCT02570035 | Pre-clinical | Completed |
| NCT00939757 | Phase 1 | Completed |
| NCT01285596 | Phase 1 | Completed |
| NCT01579461 | Phase 1 | Completed |
Competing Products
20 competing products in Pharmacokinetics